vedolizumab
takeda
['vedolizumab', 'vedo', ' vedo', 'thio', ' uc ']
 additive non-pharmacokinetic benefits of thiopurine when combined with vedolizumab especially in bio-failures and those not in histological remission at baseline in moderate-severe uc patients.
Dr Rupert Leong Sydney gastroentroenterologist endoscopist IBD @dr_rupey https://t.co/2PKVvAhB6L